Record-Breaking Revenue and Growth
Total revenue grew 49% year-over-year to a quarterly record of $71.5 million. The company raised its full-year revenue guidance to $280 million to $290 million, representing a 40% year-over-year growth at the midpoint.
Exceptional Growth of Recorlev
Recorlev revenue grew 136% year-over-year to $31.4 million, with the average number of patients on therapy increasing by 122%. This performance reinforces Recorlev's position as a key treatment option for Cushing's syndrome.
Positive Adjusted EBITDA
The company reported a positive adjusted EBITDA of $12.5 million, reflecting an improvement of nearly $13 million compared to the previous year.
Successful Analyst and Investor Day
The company's first-ever Analyst and Investor Day outlined the long-term vision and key growth drivers, notably Recorlev and the pipeline asset XP-8121, receiving positive engagement from the investment community.
Gvoke and Keveyis Steady Growth
Gvoke posted a 17% increase in revenue to $23 million, while Keveyis demonstrated its importance with revenue over $11 million, marking a modest increase.